Cost-Effectiveness Analysis of Tacrolimus Regular-Release and Sustained-Release Capsules for Prevention of Rejection After Liver Transplantation
Objective To evaluate the cost-effectiveness of tacrolimus regular-release capsules and sustained-release capsules for prevention of the rejection after liver transplantation.Methods A total of 1 520 patients underwent liver transplantation admitted to the Outpatient Department of Liver Transplantation in the Beijing Friendship Hospital,Capital Medical University from January 1,2016 to June 30,2023 were selected,1 031 of them took the regular-release capsules orally after surgery,489 took the sustained-release capsules orally,and on this basis,Mycophenolate Mofetil Capsuels(same usage and dosage)were added for immunosuppressive therapy.A Markov model was constructed by the TreeAge Pro 2021 software,with a research period of 30 years.The costs(direct medical costs)and utility parameters were collected based on the China´s healthcare system to perform the cost-effectiveness analysis of sustained-release capsules and regular-release capsules for prevention of the rejection after liver transplantation,and the model was verified by the univariate sensitivity analysis and probabilistic sensitivity analysis.Results The incremental cost-effectiveness ratio(ICER)of sustained-release capsules to regular-release capsules was CNY 159 357.86/quality-adjusted life year(QALY),which was less than the willingness-to-pay(CNY 257 094).The price,discount rate of sustained-release capsules and price of regular-release capsules had a significant effect on the model.The cost-effectiveness probability of sustained-release capsules was 63.72%within 30 years after liver transplantation.Conclusion Within 30 years after liver transplantation,sustained-release capsules have more pharmacoeconomic advantages for prevention of the rejection after liver transplantation than regular-release capsules.
万方数据
维普
